A consortium of investors, including Ascension Ventures, Catalio Capital Management, Sixty Degree Capital, Hillenbrand Capital Partners, The Rise Fund, KCK Group, PSP Investments, T. Rowe Price, Ally Bridge Partners, Venrock, Pfizer Ventures, Johnson & Johnson Innovation, led a $80m funding round in RefleXion, a therapeutic oncology company. “RefleXion’s breakthrough technology holds the potential to expand the reach of radiotherapy to late-stage cancers where five-year survival is less than 31%. We believe wholeheartedly in their goals of improving outcomes for these patients, and in prioritizing the availability of BgRT at community hospitals thereby enabling patients to receive their cancer treatment without traveling long distances,” Tara Butler, Ascension Ventures Senior Managing Director.